Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma

Javeed Iqbal, Catalina Amador, Timothy W. McKeithan, Wing C. Chan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Peripheral T-cell lymphoma (PTCL) is an uncommon group of lymphoma covering a diverse spectrum of entities. Little was known regarding the molecular and genomic landscapes of these diseases until recently but the knowledge is still quite spotty with many rarer types of PTCL remain largely unexplored. In this chapter, the recent findings from gene expression profiling (GEP) studies, including profiling data on microRNA, where available, will be presented with emphasis on the implication on molecular diagnosis, prognostication, and the identification of new entities (PTCL-GATA3 and PTCL-TBX21) in the PTCL-NOS group. Recent studies using next-generation sequencing have unraveled the mutational landscape in a number of PTCL entities leading to a marked improvement in the understanding of their pathogenesis and biology. While many mutations are shared among PTCL entities, the frequency varies and certain mutations are quite unique to a specific entity. For example, TET2 is often mutated but this is particularly frequent (70-80%) in angioimmunoblastic T-cell lymphoma (AITL) and IDH2 R172 mutations appear to be unique for AITL. In general, chromatin modifiers and molecular components in the CD28/T-cell receptor signaling pathways are frequently mutated. The major findings will be summarized in this chapter correlating with GEP data and clinical features where appropriate. The mutational landscape of cutaneous T-cell lymphoma, specifically on mycosis fungoides and Sezary syndrome, will also be discussed.

Original languageEnglish (US)
Pages (from-to)31-68
Number of pages38
JournalCancer Treatment and Research
Volume176
DOIs
StatePublished - Jan 1 2019

Fingerprint

Peripheral T-Cell Lymphoma
T-Cell Lymphoma
Gene Expression Profiling
Mutation
Sezary Syndrome
Cutaneous T-Cell Lymphoma
Mycosis Fungoides
T-Cell Antigen Receptor
MicroRNAs
Chromatin
Lymphoma

Keywords

  • Biology
  • Gene expression profiling
  • Mutational landscape
  • Mycosis fungoides
  • Pathogenesis
  • Peripheral T-cell lymphoma
  • Sezary syndrome

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma. / Iqbal, Javeed; Amador, Catalina; McKeithan, Timothy W.; Chan, Wing C.

In: Cancer Treatment and Research, Vol. 176, 01.01.2019, p. 31-68.

Research output: Contribution to journalArticle

@article{f0d79fc060a449b2aaaf13066b7d436a,
title = "Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma",
abstract = "Peripheral T-cell lymphoma (PTCL) is an uncommon group of lymphoma covering a diverse spectrum of entities. Little was known regarding the molecular and genomic landscapes of these diseases until recently but the knowledge is still quite spotty with many rarer types of PTCL remain largely unexplored. In this chapter, the recent findings from gene expression profiling (GEP) studies, including profiling data on microRNA, where available, will be presented with emphasis on the implication on molecular diagnosis, prognostication, and the identification of new entities (PTCL-GATA3 and PTCL-TBX21) in the PTCL-NOS group. Recent studies using next-generation sequencing have unraveled the mutational landscape in a number of PTCL entities leading to a marked improvement in the understanding of their pathogenesis and biology. While many mutations are shared among PTCL entities, the frequency varies and certain mutations are quite unique to a specific entity. For example, TET2 is often mutated but this is particularly frequent (70-80{\%}) in angioimmunoblastic T-cell lymphoma (AITL) and IDH2 R172 mutations appear to be unique for AITL. In general, chromatin modifiers and molecular components in the CD28/T-cell receptor signaling pathways are frequently mutated. The major findings will be summarized in this chapter correlating with GEP data and clinical features where appropriate. The mutational landscape of cutaneous T-cell lymphoma, specifically on mycosis fungoides and Sezary syndrome, will also be discussed.",
keywords = "Biology, Gene expression profiling, Mutational landscape, Mycosis fungoides, Pathogenesis, Peripheral T-cell lymphoma, Sezary syndrome",
author = "Javeed Iqbal and Catalina Amador and McKeithan, {Timothy W.} and Chan, {Wing C.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/978-3-319-99716-2_2",
language = "English (US)",
volume = "176",
pages = "31--68",
journal = "Cancer Treatment and Research",
issn = "0927-3042",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma

AU - Iqbal, Javeed

AU - Amador, Catalina

AU - McKeithan, Timothy W.

AU - Chan, Wing C.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Peripheral T-cell lymphoma (PTCL) is an uncommon group of lymphoma covering a diverse spectrum of entities. Little was known regarding the molecular and genomic landscapes of these diseases until recently but the knowledge is still quite spotty with many rarer types of PTCL remain largely unexplored. In this chapter, the recent findings from gene expression profiling (GEP) studies, including profiling data on microRNA, where available, will be presented with emphasis on the implication on molecular diagnosis, prognostication, and the identification of new entities (PTCL-GATA3 and PTCL-TBX21) in the PTCL-NOS group. Recent studies using next-generation sequencing have unraveled the mutational landscape in a number of PTCL entities leading to a marked improvement in the understanding of their pathogenesis and biology. While many mutations are shared among PTCL entities, the frequency varies and certain mutations are quite unique to a specific entity. For example, TET2 is often mutated but this is particularly frequent (70-80%) in angioimmunoblastic T-cell lymphoma (AITL) and IDH2 R172 mutations appear to be unique for AITL. In general, chromatin modifiers and molecular components in the CD28/T-cell receptor signaling pathways are frequently mutated. The major findings will be summarized in this chapter correlating with GEP data and clinical features where appropriate. The mutational landscape of cutaneous T-cell lymphoma, specifically on mycosis fungoides and Sezary syndrome, will also be discussed.

AB - Peripheral T-cell lymphoma (PTCL) is an uncommon group of lymphoma covering a diverse spectrum of entities. Little was known regarding the molecular and genomic landscapes of these diseases until recently but the knowledge is still quite spotty with many rarer types of PTCL remain largely unexplored. In this chapter, the recent findings from gene expression profiling (GEP) studies, including profiling data on microRNA, where available, will be presented with emphasis on the implication on molecular diagnosis, prognostication, and the identification of new entities (PTCL-GATA3 and PTCL-TBX21) in the PTCL-NOS group. Recent studies using next-generation sequencing have unraveled the mutational landscape in a number of PTCL entities leading to a marked improvement in the understanding of their pathogenesis and biology. While many mutations are shared among PTCL entities, the frequency varies and certain mutations are quite unique to a specific entity. For example, TET2 is often mutated but this is particularly frequent (70-80%) in angioimmunoblastic T-cell lymphoma (AITL) and IDH2 R172 mutations appear to be unique for AITL. In general, chromatin modifiers and molecular components in the CD28/T-cell receptor signaling pathways are frequently mutated. The major findings will be summarized in this chapter correlating with GEP data and clinical features where appropriate. The mutational landscape of cutaneous T-cell lymphoma, specifically on mycosis fungoides and Sezary syndrome, will also be discussed.

KW - Biology

KW - Gene expression profiling

KW - Mutational landscape

KW - Mycosis fungoides

KW - Pathogenesis

KW - Peripheral T-cell lymphoma

KW - Sezary syndrome

UR - http://www.scopus.com/inward/record.url?scp=85059267157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059267157&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-99716-2_2

DO - 10.1007/978-3-319-99716-2_2

M3 - Article

C2 - 30596212

AN - SCOPUS:85059267157

VL - 176

SP - 31

EP - 68

JO - Cancer Treatment and Research

JF - Cancer Treatment and Research

SN - 0927-3042

ER -